<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11710824</article-id><article-id pub-id-type="pmc">2375148</article-id><article-id pub-id-type="pii">6692014</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2014</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gelderblom</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Sparreboom</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jonge</surname><given-names>M J A de</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Loos</surname><given-names>W J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wilms</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Mantel</surname><given-names>M A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hennis</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Camlett</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Verweij</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Burg</surname><given-names>M E L van der</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medical Oncology, <label>2</label>Department of Pharmacy, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, Rotterdam, AE, 3075, The Netherlands</aff><aff id="aff3"><label>3</label>SmithKline Beecham Pharmaceuticals, Zeist, The Netherlands</aff><aff id="aff4"><label>4</label>Glaxo SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (South), Third Avenue, Harlow, Essex, CM19 5AW, UK</aff><aff id="aff5"><label>5</label>Department of Clinical Oncology, Leiden University Medical Centre, KI-p, PO Box 9600, Leiden, RC, 2300, The Netherlands</aff><pub-date pub-type="ppub"><month>10</month><year>2001</year></pub-date><volume>85</volume><issue>8</issue><fpage>1124</fpage><lpage>1129</lpage><history><date date-type="received"><day>16</day><month>02</month><year>2001</year></date><date date-type="rev-recd"><day>11</day><month>06</month><year>2001</year></date><date date-type="accepted"><day>05</day><month>07</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Both weekly cisplatin chemotherapy and single agent topotecan have proven to be effective in recurrent ovarian cancer. Preclinical data show synergism between cisplatin and topotecan. Side effects for this combination are drug sequence dependent and predominantly haematologic. Since preclinical data suggest that Cremophor EL (CrEL), the formulation vehicle of paclitaxel, has a protective effect on haematological toxicity of cisplatin, CrEL was added to the combination cisplatin and topotecan. In this phase I study, escalating doses of oral topotecan administered on day 1, 2, 8, 9, 15, 16, 29, 30, 36, 37, 43, 44 were combined with weekly cisplatin 70&#x02008;mg m<sup>&#x02212;2</sup>d<sup>&#x02212;1</sup>on day 1, 8, 15, 29, 36, 43 (scheme A) or with the presumably less myelotoxic sequence weekly cisplatin day 2, 9, 16, 30, 37, 44 (scheme B). In scheme C, CrEL 12&#x02008;ml was administered prior to cisplatin in the sequence of Scheme A. 18 patients have received a total of 85 courses. In scheme A 4/10 patients, all treated with topotecan 0.45&#x02008;mg m<sup>&#x02212;2</sup>d<sup>&#x02212;1</sup>, experienced DLT: 1 patient had vomiting grade 4, 1 patient had grade 4 neutropenia &#x0003e;5 days, 1 patient had &#x0003e;2 weeks delay due to thrombocytopenia and 1 patient due to neutropenia. Both patients in scheme B (topotecan 0.45&#x02008;mg m<sup>&#x02212;2</sup>d<sup>&#x02212;1</sup>) had DLT due to a delay &#x0003e;&#x02008;2 weeks because of prolonged haematological toxicity. No DLT was observed in the first 3 patients in scheme C (topotecan 0.45&#x02008;mg m<sup>&#x02212;2</sup>d<sup>&#x02212;1</sup>). However, 2 out of 3 patients treated at dose level topotecan 0.60&#x02008;mg m<sup>&#x02212;2</sup>d<sup>&#x02212;1</sup>in scheme C experienced DLT due to &#x0003e;2 weeks delay because of persistent thrombocytopenia or neutropenia. We conclude that there is a modest clinical effect of CrEL on haematological toxicity for this cisplatin-based combination regimen, which seems to reduce these side effects but does not really enable an increase of the oral topotecan dose. &#x000a9; 2001 Cancer Research Campaign<ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">&#x02002;&#x02002;http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>cisplatin</kwd><kwd>oral topotecan</kwd><kwd>cremophor EL</kwd><kwd>ovarian cancer</kwd></kwd-group></article-meta></front></article>


